Mostrar registro simples

dc.contributor.authorPérez Baena, Manuel Jesús 
dc.contributor.authorCordero Pérez, Francisco Josué
dc.contributor.authorPérez Losada, Jesús 
dc.contributor.authorHolgado Madruga, Marina 
dc.date.accessioned2026-04-14T11:41:26Z
dc.date.available2026-04-14T11:41:26Z
dc.date.issued2023-08-20
dc.identifier.citationPérez-Baena, M. J., Cordero-Pérez, F. J., Pérez-Losada, J., & Holgado-Madruga, M. (2023). The role of GAB1 in cancer. Cancers, 15(16), 4179.es_ES
dc.identifier.urihttp://hdl.handle.net/10366/170981
dc.description.abstract[EN]GRB2-associated binder 1 (GAB1) is the inaugural member of the GAB/DOS family of pleckstrin homology (PH) domain-containing proteins. Upon receiving various stimuli, GAB1 transitions from the cytoplasm to the membrane where it is phosphorylated by a range of kinases. This event recruits SH2 domain-containing proteins like SHP2, PI3K's p85 subunit, CRK, and others, thereby activating distinct signaling pathways, including MAPK, PI3K/AKT, and JNK. GAB1-deficient embryos succumb in utero, presenting with developmental abnormalities in the heart, placenta, liver, skin, limb, and diaphragm myocytes. Oncogenic mutations have been identified in the context of cancer. GAB1 expression levels are disrupted in various tumors, and elevated levels in patients often portend a worse prognosis in multiple cancer types. This review focuses on GAB1's influence on cellular transformation particularly in proliferation, evasion of apoptosis, metastasis, and angiogenesis-each of these processes being a cancer hallmark. GAB1 also modulates the resistance/sensitivity to antitumor therapies, making it a promising target for future anticancer strategies.es_ES
dc.format.mimetypeapplication/pdf
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionales_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.subjectGAB1es_ES
dc.subjectangiogenesises_ES
dc.subjectmetastasises_ES
dc.subjecttherapy resistancees_ES
dc.subjecttumorigenesises_ES
dc.subject.meshDrug Resistance *
dc.subject.meshNeoplasm Metastasis *
dc.subject.meshDrug Therapy *
dc.titleThe role of GAB1 in canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/CANCERS15164179es_ES
dc.subject.unesco3209 Farmacologíaes_ES
dc.identifier.doi10.3390/cancers15164179
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn2072-6694
dc.journal.titleCancerses_ES
dc.volume.number15es_ES
dc.issue.number16es_ES
dc.page.initial4179es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsmetástasis neoplásica *
dc.subject.decsresistencia a medicamentos *
dc.subject.decsfarmacoterapia *


Arquivos deste item

Thumbnail

Este item aparece na(s) seguinte(s) coleção(s)

Mostrar registro simples

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Exceto quando indicado o contrário, a licença deste item é descrito como Attribution-NonCommercial-NoDerivatives 4.0 Internacional